Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike

1 Jan 2020

Abstract excerpt

There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a structure-based strategy targeting highly conserved druggable regions resulting from a comprehensive large-scale sequence analysis and structural characterization of Spike...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32913581
DOI: 10.1016/j.csbj.2020.07.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV SpikePMID 32913581Read ↗

Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 VariantsSemantic proximity Read ↗

A Comprehensive Analysis of Structural and Functional Changes Induced by SARS-CoV-2 Spike Protein MutationsSemantic proximity Read ↗

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of SpikeSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

In Silico Discovery and Evaluation of Inhibitors of the SARS-CoV-2 Spike Protein–HSPA8 Complex Towards Developing COVID-19 Therapeutic DrugsSemantic proximity Read ↗

Structural evolution of Delta lineage of SARS-CoV-2.Semantic proximity Read ↗

Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics developmentSemantic proximity Read ↗

Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 PandemicSemantic proximity Read ↗

Architects of infection: A structural overview of SARS-related coronavirus spike glycoproteinsSemantic proximity Read ↗

Identification of a Druggable Site on GRP78 at the GRP78-SARS-CoV-2 Interface and Compounds to Disrupt that InterfaceSemantic proximity Read ↗

In-silico analysis of potential interaction of drugs and the SARS-CoV-2 spike proteinSemantic proximity Read ↗

From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.